PPARβ/δ‐agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Astrocytes are the gatekeepers of neuronal energy supply. In neurodegenerative diseases, bioenergetics demand increases and becomes reliant upon fatty acid oxidation as a source of energy. Defective fatty acid oxidation and mitochondrial dysfunctions correlate with hippocampal neurodegeneration and memory deficits in Alzheimer's disease (AD), but it is unclear whether energy metabolism can be targeted to prevent or treat the disease. Here we show for the first time an impairment in fatty acid oxidation in human astrocytes derived from induced pluripotent stem cells of AD patients. The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARβ/δ) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism. GW0742 enhanced the expression of CPT1a, the gene encoding for a rate‐limiting enzyme of fatty acid oxidation. Similarly, treatment of a mouse model of AD, the APP/PS1‐mice, with GW0742 increased the expression of Cpt1a and concomitantly reversed memory deficits in a fear conditioning test. Although the GW0742‐treated mice did not show altered astrocytic glial fibrillary acidic protein‐immunoreactivity or reduction in amyloid beta (Aβ) load, GW0742 treatment increased hippocampal neurogenesis and enhanced neuronal differentiation of neuronal progenitor cells. Furthermore, GW0742 prevented Aβ‐induced impairment of long‐term potentiation in hippocampal slices. Collectively, these data suggest that PPARβ/δ‐agonism alleviates AD related deficits through increasing fatty acid oxidation in astrocytes and improves cognition in a transgenic mouse model of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
Astrocyte-Neuron Lactate Transport Is Required for Long-Term Memory Formation
Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., & Alberini, C. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.018 · Cited by 1,711
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 3×
“For behavioral testing and immunohistochemistry, we used 21 C57BL/6J wild type (WT) and 19 transgenic (TG) APPswe/ PSEN1dE9 mice (Jankowsky et al., 2004) (Jackson Laboratories, Bar Harbor, ME) carrying human APP (K595N and M596L) and PSEN1dE9 mutations maintained in C57BL/6J background.”
BackgroundMethodRegulation of Muscle Fiber Type and Running Endurance by PPARδ
Wang, Y.-X., Zhang, C.-L., Yu, R. T., Cho, H. K., Nelson, M. C., Bayuga-Ocampo, C. R., Ham, J., Kang, H., & Evans, R. M. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020294 · Cited by 1,089
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744
Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.197 · Cited by 727 · cited 2×
“In line with previous studies (Kilgore et al., 2010), vehicle treated APP/PS1 mice exhibited a significant reduction in conditional freezing compared to WT mice (t(38) = 3.”
Ebert, D., Haller, R. G., & Walton, M. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05928.2003 · Cited by 427
Kimura, R., & Ohno, M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.006 · Cited by 333
PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease
Oksanen, M., Petersen, A. J., Naumenko, N., Puttonen, K., Lehtonen, Š., Gubert Olivé, M., Shakirzyanova, A., Leskelä, S., Sarajärvi, T., Viitanen, M., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.016 · Cited by 332 · cited 10×
“(Oksanen et al., 2017), yet GW0742 failed to alter the basal glycolytic”
BackgroundMethodInfluentialSelf-citationLalonde, R., Kim, H. D., Maxwell, J. A., & Fukuchi, K. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.08.028 · Cited by 170
Cited by
Modeling Alzheimer’s disease with iPSC-derived brain cells
Penney, J., Ralvenius, W. T., & Tsai, L.-H. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0468-3 · Cited by 471
Mi, Y., Qi, G., Vitali, F., Shang, Y., Raikes, A. C., Wang, T., Jin, Y., Brinton, R. D., Gu, H., & Yin, F. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00756-4 · Cited by 343
Rose, J., Brian, C., Pappa, A., Panayiotidis, M. I., & Franco, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.536682 · Cited by 196
Lipid metabolism in astrocytic structure and function
Lee, J. A., Hall, B., Allsop, J., Alqarni, R., & Allen, S. P. (2021) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.07.017 · Cited by 116
Neuron-astrocyte transmitophagy is altered in Alzheimer's disease
Lampinen, R., Belaya, I., Saveleva, L., Liddell, J. R., Rait, D., Huuskonen, M. T., Giniatullina, R., Sorvari, A., Soppela, L., Mikhailov, N., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105753 · Cited by 97
“Levels of S100a4 in astrocytes are increased after head trauma and in astrocytes under stress (Dmytriyeva et al., 2012; Kozlova and Lukanidin, 2002).”
BackgroundResultSelf-citationPomeshchik, Y., Klementieva, O., Gil, J., Martinsson, I., Hansen, M. G., de Vries, T., Sancho-Balsells, A., Russ, K., Savchenko, E., Collin, A., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.06.001 · Cited by 95
“Cellular pathology was recently examined in iPSC-derived microglia (Konttinen et al., 2019a), a cell type that plays an important role in AD pathology (Venegas et al., 2017).”
BackgroundGarcia, G., Pinto, S., Ferreira, S., Lopes, D., Serrador, M. J., Fernandes, A., Vaz, A. R., Mendonça, A. D., Edenhofer, F., Malm, T., et al. (2022) · Cells · doi:10.3390/cells11213377 · Cited by 55
“iPSC-derived astrocytes from AD patients showed the enhanced release of Aβ42, altered calcium homeostasis, increased ROS production and inflammatory cytokine release, among other features [27,119].”
BackgroundSelf-citationVillar-Vesga, J., Henao-Restrepo, J., Voshart, D. C., Aguillon, D., Villegas, A., Castaño, D., Arias-Londoño, J. D., Zuhorn, I. S., Ribovski, L., Barazzuol, L., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.587989 · Cited by 29
Qu, W., Canoll, P., & Hargus, G. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.006 · Cited by 24
iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype
Sullivan, M. A., Lane, S. D., McKenzie, A. D. J., Ball, S. R., Sunde, M., Neely, G. G., Moreno, C. L., Maximova, A., Werry, E. L., & Kassiou, M. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02951-2 · Cited by 23
Neuroglia in neurodegeneration: Alzheimer, Parkinson, and Huntington disease
Lim, D., Matute, C., Cavaliere, F., & Verkhratsky, A. (2025) · Handbook of Clinical Neurology · doi:10.1016/b978-0-443-19102-2.00012-0 · Cited by 8
Bell, S. M., Wareing, H., Hamshaw, A., De, S., New, E., Shaw, P. J., De Marco, M., Venneri, A., Blackburn, D. J., Ferraiuolo, L., et al. (2023) · doi:10.1101/2023.03.23.534020 · Cited by 1
Metadata
- Authors
- Konttinen, H., Gureviciene, I., Oksanen, M., Grubman, A., Loppi, S., Huuskonen, M. T., Korhonen, P., Lampinen, R., Keuters, M., Belaya, I., Tanila, H., Kanninen, K. M., Goldsteins, G., Landreth, G., Koistinaho, J., & Malm, T.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2018-11-19
- Volume
- 67
- Issue
- 1
- Pages
- 146-159
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2901611520
- Cited by
- 52
- References
- 15
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.